← Leaderboards
Mark A Kay
Stanford University
$46,920,488
Attributed
$55,198,610
Total exposure
18
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,700,889 · 19
By mechanism
R01$38,666,335 · 8
U01$24,817,725 · 4
UC4$3,604,708 · 1
R37$3,515,317 · 1
U19$80,804 · 2
R13$16,000 · 1
Top collaborators
- Markus Grompe11 shared
- Klaus H. Kaestner6 shared
- Philip R Streeter6 shared
- Hiroyuki Nakai5 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoLiverGene TherapyCellsVectorMediatingGenesHepatocyteAdeno-Associated Viral VectorBaseGenomeTissuesHemophilia BMouse ModelGene ExpressionGene TransferDosePre-ClinicalSuccessAnimal ModelClinical TrialsGenetic TranscriptionVariantBiological
Grant awards (111)
AAV capsid engineering for enhancing gene transfer$753,381
R01 · FY2025 · AI · contact PI
Hepatic gene transfer for the treatment of hemophilia B and other genetic diseases$701,310
R01 · FY2025 · HL · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$699,711
R37 · FY2025 · AI · contact PI
3' tsRNAs: biologic function and pre-clinical targeting for treating human disease$545,421
R01 · FY2025 · CA · contact PI
Hepatic gene transfer for the treatment of hemophilia B and other genetic diseases$701,277
R01 · FY2024 · HL · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$699,711
R37 · FY2024 · AI · contact PI
AAV capsid engineering for enhancing gene transfer$696,224
R01 · FY2024 · AI · contact PI
3' tsRNAs: biologic function and pre-clinical targeting for treating human disease$518,152
R01 · FY2024 · CA · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$699,713
R37 · FY2023 · AI · contact PI
AAV capsid engineering for enhancing gene transfer$696,800
R01 · FY2023 · AI · contact PI
3' tsRNAs: biologic function and pre-clinical targeting for treating human disease$545,950
R01 · FY2023 · CA · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$708,016
R37 · FY2022 · AI · contact PI
Gene Therapy for Diabetes$699,431
U01 · FY2022 · DK
AAV capsid engineering for enhancing gene transfer$697,416
R01 · FY2022 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$697,224
R01 · FY2022 · HL · contact PI
Gene Therapy for Diabetes$720,877
U01 · FY2021 · DK
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$708,166
R37 · FY2021 · AI · contact PI
AAV capsid engineering for enhancing gene transfer$697,526
R01 · FY2021 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$697,224
R01 · FY2021 · HL · contact PI
Gene Therapy for Diabetes$729,093
U01 · FY2020 · DK
AAV capsid engineering for enhancing gene transfer$713,439
R01 · FY2020 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$697,224
R01 · FY2020 · HL · contact PI
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications$489,147
R01 · FY2020 · DK · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$456,461
R01 · FY2020 · AI · contact PI
Gene Therapy for Diabetes$743,871
U01 · FY2019 · DK
Hepatic Gene Transfer for Treatment of Hemophilias A & B$697,224
R01 · FY2019 · HL · contact PI
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries$593,119
R01 · FY2019 · AI · contact PI
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications$510,305
R01 · FY2019 · DK · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$456,461
R01 · FY2019 · AI · contact PI
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries$593,119
R01 · FY2018 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$555,896
R01 · FY2018 · HL · contact PI
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications$513,573
R01 · FY2018 · DK · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$481,343
R01 · FY2018 · AI · contact PI
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries$593,119
R01 · FY2017 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$553,368
R01 · FY2017 · HL · contact PI
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications$527,823
R01 · FY2017 · DK · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$481,343
R01 · FY2017 · AI · contact PI
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries$593,119
R01 · FY2016 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$551,004
R01 · FY2016 · HL · contact PI
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases$481,343
R01 · FY2016 · AI · contact PI
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries$593,119
R01 · FY2015 · AI · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$549,017
R01 · FY2015 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$453,663
R01 · FY2015 · AI · contact PI
In vivo targeting of diabetes-relevant human cell types with rAAV vectors$3,604,708
UC4 · FY2014 · DK
Hepatic Gene Transfer for Treatment of Hemophilias A & B$536,089
R01 · FY2014 · HL · contact PI
Studies on RNAi Based Delivery in Vivo$515,649
R01 · FY2014 · DK · contact PI
RNAi for the Treatment of Viral Hepatitis$453,663
R01 · FY2014 · AI · contact PI
Novel Sources of Transplantable Beta-cell Replacements$287,435
U01 · FY2014 · DK
Novel Sources of Transplantable Beta-cell Replacements$99,998
U01 · FY2014 · DK
Novel Sources of Transplantable Beta-cell Replacements$1,326,946
U01 · FY2013 · DK
Hepatic Gene Transfer for Treatment of Hemophilias A & B$520,771
R01 · FY2013 · HL · contact PI
Studies on RNAi Based Delivery in Vivo$506,503
R01 · FY2013 · DK · contact PI
RNAi for the Treatment of Viral Hepatitis$426,443
R01 · FY2013 · AI · contact PI
Novel Sources of Transplantable Beta-cell Replacements$1,375,235
U01 · FY2012 · DK
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors$553,305
R01 · FY2012 · HL · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$547,029
R01 · FY2012 · HL · contact PI
Studies on RNAi Based Delivery in Vivo$533,921
R01 · FY2012 · DK · contact PI
RNAi for the Treatment of Viral Hepatitis$453,663
R01 · FY2012 · AI · contact PI
Novel Sources of Transplantable Beta-cell Replacements$1,085,949
U01 · FY2011 · DK
Hepatic Gene Transfer for Treatment of Hemophilias A & B$579,815
R01 · FY2011 · HL · contact PI
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors$555,213
R01 · FY2011 · HL · contact PI
Studies on RNAi Based Delivery in Vivo$542,790
R01 · FY2011 · DK · contact PI
RNAi for the Treatment of Viral Hepatitis$453,945
R01 · FY2011 · AI · contact PI
Novel Sources of Transplantable Beta-cell Replacements$1,085,951
U01 · FY2010 · DK
Studies on RNAi Based Delivery in Vivo$654,135
R01 · FY2010 · DK · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A & B$587,482
R01 · FY2010 · HL · contact PI
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors$557,152
R01 · FY2010 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$374,072
R01 · FY2010 · AI · contact PI
RNAi for the Treatment of Viral Hepatitis$183,150
R01 · FY2010 · AI · contact PI
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors$553,871
R01 · FY2009 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$377,602
R01 · FY2009 · AI · contact PI
Studies on RNAi Based Delivery in Vivo$319,222
R01 · FY2009 · DK · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A&B$513,056
R01 · FY2008 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$377,376
R01 · FY2008 · AI · contact PI
Studies on RNAi Based Delivery in Vivo$318,992
R01 · FY2008 · DK · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A&B$508,011
R01 · FY2007 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$384,442
R01 · FY2007 · AI · contact PI
Studies on RNAi Based Delivery in Vivo$325,280
R01 · FY2007 · DK · contact PI
Hepatic Gene Transfer for Treatment of Hemophilias A&B$507,684
R01 · FY2006 · HL · contact PI
RNAi for the Treatment of Viral Hepatitis$395,707
R01 · FY2006 · AI · contact PI
Studies on RNAi Based Delivery in Vivo$346,766
R01 · FY2006 · DK · contact PI
Improved Adenoviral Vectors for Hepatic Gene Therapy$314,291
R01 · FY2006 · DK · contact PI
Gene Therapy for Hemophilia$2,146,255
U01 · FY2005 · HL
Hepatic Gene Transfer for Treatment of Hemophilias A&B$504,498
R01 · FY2005 · HL
Novel AAVs for Gene Therapy$414,710
U01 · FY2005 · HL
Improved Adenoviral Vectors for Hepatic Gene Therapy$321,783
R01 · FY2005 · DK
RNAi - based Therapies for HCV Infection$80,804
U19 · FY2005 · AI
GENE THERAPY FOR HEMOPHILIA AND CORONARY ARTERY DISEASE$2,687,829
U01 · FY2004 · HL
Improved Adenoviral Vectors for Hepatic Gene Therapy$321,715
R01 · FY2004 · DK
GENE THERAPY FOR HEMOPHILIA AND CORONARY ARTERY DISEASE$2,702,124
U01 · FY2003 · HL
HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &B$451,567
R01 · FY2003 · HL
Improved Adenoviral Vectors for Hepatic Gene Therapy$320,040
R01 · FY2003 · DK
GENE THERAPY FOR HEMOPHILIA AND CORONARY ARTERY DISEASE$2,672,209
U01 · FY2002 · HL
HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &B$439,648
R01 · FY2002 · HL
Isolated liver perfusion rAAV &nonviral vector delivery$248,650
U01 · FY2002 · HL
IMPROVED ADENOVIRAL VECTORS FOR HEPATIC GENE THERAPY$47,100
R01 · FY2002 · DK
Core--Vector production$0
P01 · FY2002 · AR
MOUSE MODEL FOR HCV INFECTION$0
U19 · FY2002 · AI
Transposon based gene therapeutics$0
P01 · FY2002 · AR
GENE THERAPY FOR HEMOPHILIA AND CORONARY ARTERY DISEASE$2,644,211
U01 · FY2001 · HL
HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &B$426,844
R01 · FY2001 · HL
IMPROVED ADENOVIRAL VECTORS FOR HEPATIC GENE THERAPY$283,887
R01 · FY2001 · DK
Isolated liver perfusion rAAV &nonviral vector delivery$248,650
U01 · FY2001 · HL
CONFERENCE ON GENE THERAPY 2001: A GENE ODYSSEY$16,000
R13 · FY2001 · DK
MOUSE MODEL FOR HCV INFECTION$0
U19 · FY2001 · AI
GENE THERAPY FOR HEMOPHILIA AND CORONARY ARTERY DISEASE$2,649,651
U01 · FY2000 · HL
HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &B$414,411
R01 · FY2000 · HL
IMPROVED ADENOVIRAL VECTORS FOR HEPATIC GENE THERAPY$275,618
R01 · FY2000 · DK
Isolated liver perfusion rAAV &nonviral vector delivery$248,650
U01 · FY2000 · HL
MOUSE MODEL FOR HCV INFECTION$0
U19 · FY2000 · AI
MOUSE MODEL FOR HCV INFECTION$0
U19 · FY2000 · AI